Decision Making in Health and Medicine: Estimation, calibration, and validation
暂无分享,去创建一个
John B. Wong | Joseph S. Pliskin | M. G. Myriam Hunink | Paul Glasziou | Milton C. Weinstein | Eve Wittenberg | Michael Drummond | M. Drummond | M. Weinstein | P. Glasziou | J. Wong | E. Wittenberg | J. Pliskin | M. Hunink | M. Hunink
[1] J. Wong,et al. Watchful Waiting with Periodic Liver Biopsy versus Immediate Empirical Therapy for Histologically Mild Chronic Hepatitis C: A Cost-Effectiveness Analysis , 2000, Annals of Internal Medicine.
[2] L. Goldman,et al. The recent decline in mortality from coronary heart disease, 1980-1990. The effect of secular trends in risk factors and treatment. , 1997, JAMA.
[3] M. Rawlins. De testimonio: on the evidence for decisions about the use of therapeutic interventions , 2008, The Lancet.
[4] S. Palmer,et al. The CHD challenge: comparing four cost-effectiveness models. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[5] Yen Lin Chia,et al. Simulation-based parameter estimation for complex models: a breast cancer natural history modelling illustration , 2004, Statistical methods in medical research.
[6] J. Savarino,et al. Bayesian Calibration of Microsimulation Models , 2009, Journal of the American Statistical Association.
[7] S G Pauker,et al. Kidney Failure or Cancer , 1984, Medical decision making : an international journal of the Society for Medical Decision Making.
[8] Natasha K. Stout,et al. Chapter 7: The Wisconsin Breast Cancer Epidemiology Simulation Model , 2006 .
[9] Ersen B. Colkesen,et al. Validation of a model to investigate the effects of modifying cardiovascular disease (CVD) risk factors on the burden of CVD: the rotterdam ischemic heart disease and stroke computer simulation (RISC) model , 2012, BMC Medicine.
[10] William Hollingworth,et al. Model Transparency and Validation , 2012, Medical decision making : an international journal of the Society for Medical Decision Making.
[11] D. Berry,et al. Effect of screening and adjuvant therapy on mortality from breast cancer , 2005 .
[12] S. Goldie,et al. Cost-Effectiveness of Human Papillomavirus Vaccination and Cervical Cancer Screening in Women Older Than 30 Years in the United States , 2009, Annals of Internal Medicine.
[13] Milton C. Weinstein,et al. Incorporating Calibrated Model Parameters into Sensitivity Analyses , 2012, PharmacoEconomics.
[14] G Scott Gazelle,et al. Calibration of disease simulation model using an engineering approach. , 2009, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[15] M. Weinstein,et al. Life Expectancy Biases in Clinical Decision Modeling , 1995, Medical decision making : an international journal of the Society for Medical Decision Making.
[16] S. Love,et al. Survival Analysis Part II: Multivariate data analysis – an introduction to concepts and methods , 2003, British Journal of Cancer.
[17] B. Gage,et al. Cost-Effectiveness of Using Pharmacogenetic Information in Warfarin Dosing for Patients With Nonvalvular Atrial Fibrillation , 2009, Annals of Internal Medicine.
[18] Neff Walker,et al. Mathematical models in the evaluation of health programmes , 2011, The Lancet.
[19] Cathal Walsh,et al. Bayesian Calibration of a Natural History Model with Application to a Population Model for Colorectal Cancer , 2011, Medical decision making : an international journal of the Society for Medical Decision Making.
[20] David G. Kleinbaum,et al. Survival Analysis: A Self-Learning Text , 1997 .
[21] Simon G Thompson,et al. Uncertainty and validation of health economic decision models. , 2009, Health economics.
[22] Natasha K. Stout,et al. Calibration Methods Used in Cancer Simulation Models and Suggested Reporting Guidelines , 2012, PharmacoEconomics.
[23] M. D. John B. Wong Washington. Pharmacogenomics of hepatitis C and decision analysis: A glimpse into the future , 2003 .
[24] Milton C. Weinstein,et al. Recent Developments in Decision-Analytic Modelling for Economic Evaluation , 2012, PharmacoEconomics.
[25] P Barton,et al. The use of modelling to evaluate new drugs for patients with a chronic condition: the case of antibodies against tumour necrosis factor in rheumatoid arthritis. , 2004, Health technology assessment.
[26] J R Beck,et al. A convenient approximation of life expectancy (the "DEALE"). I. Validation of the method. , 1982, The American journal of medicine.
[27] J B Wong,et al. Analytic Choices in Economic Models of Treatments for Rheumatoid Arthritis: What Makes a Difference? , 2005, Medical decision making : an international journal of the Society for Medical Decision Making.
[28] John B Wong,et al. Pharmacogenomics of hepatitis C and decision analysis: A glimpse into the future , 2002, Hepatology.
[29] A. O'Hagan,et al. Bayesian calibration of computer models , 2001 .
[30] C. Schmitt,et al. Barrett's esophagus: a new look at surveillance based on emerging estimates of cancer risk. , 1999 .
[31] Amy B. Knudsen,et al. Evaluating Test Strategies for Colorectal Cancer Screening: A Decision Analysis for the U.S. Preventive Services Task Force , 2008, Annals of Internal Medicine.
[32] Vivek Pawar,et al. Methods of Model Calibration , 2012, PharmacoEconomics.
[33] Karen M Kuntz,et al. Multiparameter calibration of a natural history model of cervical cancer. , 2007, American journal of epidemiology.
[34] Milton C Weinstein,et al. Calibrating longitudinal models to cross-sectional data: the effect of temporal changes in health practices. , 2011, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[35] Erry,et al. Cost effectiveness of thrombolytic therapy with tissue plasminogen activator as compared with streptokinase for acute myocardial infarction. , 1995, The New England journal of medicine.
[36] Richard G. White,et al. Calibrating Models in Economic Evaluation , 2012, PharmacoEconomics.
[37] Murray Krahn,et al. Conceptualizing a Model , 2012, Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research.
[38] Theo Stijnen,et al. Apparent and Internal Validity of a Monte Carlo–Markov Model for Cardiovascular Disease in a Cohort Follow-up Study , 2006, Medical decision making : an international journal of the Society for Medical Decision Making.